The predictive value of serum specific IgE, skin prick test (SPT), and history of prior reaction for IgE-mediated almond hypersensitivity remains unknown. This was assessed by evaluating almond open oral food challenge (OFC) outcomes in a clinical setting. METHODS: 583 OFCs were analyzed for patients from 11 months to 67 years (mean: 10.1 years). Notes and flowsheets were reviewed for outcomes. Analysis using Fisher's exact tests or t-tests were performed. RESULTS: Median almond IgE was 0.89 kU/L (range: <0.35, >100) and median SPT was 4.0 mm (range: 0, 28). 114 (20%) had both negative almond SPT and IgE. Fifty-two (12%) had a history of prior almond reaction. Outcomes included 529 passes (91%), 29 (5%) failures, and 23 (4%) indeterminate. Nineteen (3%) had objective signs consistent with immediate hypersensitivity. Eight (1.3%) had severe symptoms including angioedema, respiratory, or objective gastrointestinal symptoms. Failures were associated with higher almond IgE (p<0.001), larger almond wheal (p50.001), positive history of prior reaction (p<0.034), and higher peanut IgE (p<0.001). Failures with objective signs were associated with younger age and higher IgE to pistachio (p<0.019), cashew (p<0.041), pecan (p<0.021), walnut (p<0.008), and hazelnut (p<0.029). The combination of almond IgE, almond wheal, and age demonstrated good predictive ability for IgE-mediated reactions (AUC 0.85). Twenty failures (69%) received antihistamines alone, 1 (3%) received albuterol, and 2 (7%) received intramuscular epinephrine. CONCLUSIONS: Almond challenges were associated with a low rate of failures (5%). Almond IgE, SPT, and clinical history may be useful in predicting IgE-mediated reactions. Severe reactions including anaphylaxis are still possible.
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Threshold doses during positive (failed) peanut challenges Michaela E. Nolan, Xanthi Pantazelos, Tander Simberloff, Dionne Graham, and Andrew J. MacGinnitie, MD PhD FAAAAI; Boston Children's Hospital, Boston, MA. RATIONALE: Food challenges are the gold standard for establishing the presence or absence of food allergy. There is little data on what dose of antigen patients react to (failing dose) and how that relates to reaction severity. METHODS: We collected data on 1062 food challenges (approximately 20% for peanut) done at our institution in 2 different settings. Patients judged to be at low risk underwent 3-step challenges in a clinic setting while those at higher risk underwent challenges of 3 to 6 steps in an infusion center. Among patients with reactions, the dose at which the reaction occurred and the severity of reaction based on need for epinephrine were recorded. RESULTS: 24% of challenges were positive (failed); 5% required epinephrine. Across all challenges 47% (93/198) of failures occurred on the first dose (100 or 500 mg depending on location) and the rate was similar across settings. Among positive challenges for peanut, 62% of high risk challenges reacted at the lowest increment (100 mg) compared with 46% of low risk of challenges. Skin test and serum specific IgE testing did not differ between positive and negative challenges. 42% (24/57) of patients with mild subjective symptoms who proceeded to further doses eventually passed their challenge, including 7 of 9 peanut challenges. CONCLUSIONS: Food challenges can be safely conducted in the outpatient setting. Almost half of patients react on the first dose including >60% of high risk peanut challenges at 100 mg. Many patients with mild subjective symptoms go on to pass their challenge.
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Ara h 2 spIgE levels are associated with outcome of open peanut challenges Aoife Marie Gallagher, MB 1 , and Jonathan O'B. Hourihane, MD FAAAAI 2 ; 1 University College Cork,Ireland, Cork, Ireland, 2 University College Cork, Cork, Ireland. RATIONALE: Oral food challenges (OFC) are resource dependent and time-consuming. Patient selection is important for reasons of both resource efficiency and safety. Parents often wish to know how likely their child is to pass (or fail) OFC. We examined the relationship between Ara h 2 spIgE levels and peanut challenge outcome in routine allergy care. METHODS: Analysis of prospectively collected demographic and spIgE data on peanut OFC performed in a university-based paediatric allergy service. Ara h 2 spIgE is reported in KU A /L. RESULTS: 723 children had a peanut OFC since 2007. 121 had Ara h 2 measured. 7 were excluded, 65 (57%) had a positive OFC, 48 (42%) negative, 1 inconclusive. 7/65 positive OFC (10.7%) had Ara h 2 spIgE <0.1, 31 (47.7%) 0.1-1.9, and 27 (41.5%) >2.0. 23/48 negative OFC (48%) had Ara h 2 spIgE <0.1, 24 (50%) 0.1-1.9 and only 1 (2%) had an Ara h 2 spIgE >2.0. 68% of subjects with Ara h 2 spIgE <0.1 had negative OFC, increasing to 76.47% (13/17) in children with no history of clinical reaction to peanut. Of the remaining 4, 3 had mild reactions (angioedema/urticaria) and 1 had severe reaction (wheeze). CONCLUSIONS: Ara h 2 spIgE measurement is useful for predicting results of peanut OFC with >95% sensitivity if >2.0 and Ara h 2 <0.1 having 76% specificity in children without clinical reactivity to peanut. OFC is still needed even with low Ara h 2 spIgE levels as OFC can still cause a severe reaction in such patients
